CogState Akcija

CogState EPS

Delisted·2026. g. 15. jūn.

Peļņa uz akciju (EPS) no CogState (CGS.AX) uz 2026. g. 22. aug. ir 0,06 USD. Iepriekšējā gadā Peļņa uz akciju (EPS) bija 0,03 USD — izmaiņas 85,17 % (augstāks).

EPS

0,06USD

YoY

85,17%

Pēdējoreiz atjaunināts:

Peļņa uz akciju (EPS) no CogState ir 2026 0,06 USD. Peļņa uz akciju (EPS) no CogState bija 2025 0,03 USD. Tas samazinās par 85,17% augstāks salīdzinājumā ar iepriekšējo gadu.
Access this data via the Eulerpool API

CogState Akciju analīze

Ko dara CogState? CogState Ltd is an Australian company specializing in the development of innovative cognitive tests. The company was founded in 1999 and is based in Melbourne, Australia. It conducts computer-based cognitive tests to gather information about the cognitive functioning of patients and athletes. The CogState tests are specifically designed to measure cognitive abilities in areas such as perception, reaction time, memory, and attention. The business model of CogState is based on the development, marketing, and sale of cognitive test products. The company generates a significant portion of its revenue through licensing its tests to pharmaceutical and biotech companies that want to test their medications or therapies more effectively. CogState also has a strong presence in the sports industry, offering its tests to sports teams and individual athletes. CogState was founded in 1999 by Paul Maruff, a neuropsychologist, who was searching for better and more effective ways to conduct cognitive tests. Initially, the tests developed by CogState were exclusively for medical research, but it was quickly discovered that they could be useful in other areas as well. In 2004, Richard Kimber joined the company as CEO and Chairman, bringing his experience from the biotechnology industry. CogState offers a variety of cognitive tests for various applications, including clinical trials, sports performance analysis, and brain injury treatment. The tests are licensed by different companies and organizations that use them to test the effects of medications and therapies on cognitive functions or to assess performance and injuries in sports. One example of a CogState product is the AX Continuous Tracker Test. This test was developed for clinical use and allows for continuous and accurate measurement of cognitive functions in patients with psychiatric and neurological disorders. Another application is the SPARQ test for athletes, which allows for the measurement and improvement of athletes' cognitive abilities. In summary, CogState Ltd is a leading company in the field of cognitive tests. The company specializes in developing innovative cognitive tests for the specific requirements of pharmaceutical and biotech companies, as well as sports organizations. The tests are used worldwide by various organizations and have a significant impact on the treatment of psychiatric and neurological disorders, as well as performance and injury analysis in sports. CogState ir viens no populārākajiem uzņēmumiem Eulerpool.

Bieži uzdotie jautājumi par CogState akciju

CogState Peļņa uz akciju (EPS) 2026. gadā ir 0,06 USD.

Peļņa uz akciju (EPS) no CogState mainījās no 0,03 USD uz 0,06 USD, kas atspoguļo 85,17 % izmaiņas. Vērtība ir augstāks nekā iepriekšējā gadā.

Vietnē Eulerpool varat atrast pilnīgu Peļņa uz akciju (EPS) CogState vēsturisko attīstību kopš 2006. gada — ar gada vērtībām, grafikiem un detalizētu analīzi.

Peļņa uz akciju mēra uzņēmuma peļņas daļu, sadalītu katrai apgrozībā esošajai akcijai.

EPS = Neto peļņa / Izdotās akcijas

Access this data via the Eulerpool API

Peļņas un zaudējumu aprēķins — CogState

Visas kategorijas